Brief Summary
To assess the freedom from local failure at 12 months after Stereotactic Body Radiotherapy (SBRT). Also to assess the safety, efficacy and feasibility of SBRT in the treatment of high risk localised pancreatic cancer.
Intervention / Treatment
- Radiation: Stereotactic Body Radiotherapy (SBRT)
Inclusion Criteria
- Age ≥ 18 and able to give informed consent
- Patients with histologically or cytologically confirmed locally advancedat a late stage, far along adenocarcinomacancer arising from mucus-producing glands in organs of the pancreas, including patients with extrapancreatic extension (Stage IIA), node positive (Stage IIB), borderline resectable or locally advanced as defined by AGITG guidelines
- ECOG performance status 0-1
- Measurable disease as defined by RECIST 1.1
- Have received or plan to receive chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells
- Successful insertion of fiducial markers